Blann A D, McCollum C N
Department of Surgery, University Hospital of South Manchester, Didsbury, U.K.
Eur J Vasc Surg. 1994 Jan;8(1):10-5. doi: 10.1016/s0950-821x(05)80112-4.
von Willebrand factor (vWf) is an interesting and potentially important molecule whose biology in health and disease warrants attention. A growing body of knowledge now suggests that plasma levels of this specific product of the endothelial cell may have potential as a marker for the assessment of endothelial injury in vivo. As its functions include platelet aggregation and mediation of platelet adhesion to the subendothelium, it may also have a role in the pathogenesis of progression of atherosclerosis. In comparison to asymptomatic controls, increased levels of vWf are found in atherosclerotic vascular disease and in the presence of several of its major risk factors (smoking, hypercholesterolaemia, hypertension, obesity and diabetes). High plasma levels of vWf are also associated with the prediction of adverse clinical events such as myocardial infarction and poor outcome following arterial surgery, possibly by the promotion of thrombus formation. These and other studies indicate that research directed towards determining whether therapy to reduce levels of vWf also influences the progression of arterial disease should prove to be profitable.
血管性血友病因子(vWf)是一种有趣且可能具有重要意义的分子,其在健康与疾病中的生物学特性值得关注。目前越来越多的知识表明,这种内皮细胞特异性产物的血浆水平可能具有作为体内评估内皮损伤标志物的潜力。由于其功能包括血小板聚集以及介导血小板黏附于内皮下,它在动脉粥样硬化进展的发病机制中可能也发挥着作用。与无症状对照组相比,在动脉粥样硬化性血管疾病及其几种主要危险因素(吸烟、高胆固醇血症、高血压、肥胖和糖尿病)存在时,vWf水平会升高。血浆vWf水平升高还与不良临床事件的预测相关,如心肌梗死以及动脉手术后的不良预后,这可能是通过促进血栓形成实现的。这些研究及其他研究表明,旨在确定降低vWf水平的治疗是否也会影响动脉疾病进展的研究应该会有成效。